Menu
← Oncology Approval Tracker
FDA DECISION ·
Lifyorli + nab-paclitaxel
relacorilant with nab-paclitaxel · Corcept Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three systemic regimens, including at least one with bevacizumab.
LAMPGEN ANALYSIS
Why it matters
This adds a glucocorticoid receptor antagonist to a taxane regimen in a defined previously treated population. The prior bevacizumab requirement matters for applicability.
What research teams should watch
Capture platinum resistance timing, prior bevacizumab and concurrent glucocorticoid use. Separate label eligibility from trial exclusions.
PRIMARY RECORDS